Brief: India's Marksans Pharma Sept-Quarter Consol Net Profit Rises
14/11/2022 14:34
Nov 14 (Reuters) - Marksans Pharma Ltd MARK.NS :
* SEPT-QUARTER CONSOL NET PROFIT 612.5 MILLION RUPEES
VERSUS
PROFIT 454.9 MILLION RUPEES
* SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.53 BILLION
RUPEES
VERSUS 3.61 BILLION RUPEES
Source text for Eikon: ID:nBSEnrXYR
Further company coverage: MARK.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg